BETA-ADRENOBLOCKER THERAPY IN ARTERIAL HYPERTENSION, METABOLIC DISTURBANCES, AND TYPE 2 DIABETES MELLITUS
Abstract
The paper presents modern views on beta-blocker therapy in clinical practice. The beta-blocker group is heterogeneous in terms of clinical usage. The recent critical comments by some researchers on beta-blocker therapy should not misguide the practitioners, who always need to ask themselves the key question: what specific beta-blockers are discussed. In fact, some beta-blockers, especially non-selective ones, could demonstrate negative effects and are contraindicated in specific clinical situations. The problem of negative metabolic influences is particularly important for the patients with metabolic syndrome and Type 2 diabetes mellitus (DM-2). However, modern super-selective beta-blockers did not have these negative effects and could be widely used in clinical practice, even in patients with metabolic syndrome and DM-2.
About the Authors
D. V. Nebieridze
ФГУ ГНИЦПМ Росмедтехнологии, Москва
Russian Federation
Russian Federation
R. G. Kulieva
ФГУ ГНИЦПМ Росмедтехнологии, Москва
Russian Federation
Russian Federation
V. D. Sargsyan
ФГУ ГНИЦПМ Росмедтехнологии, Москва
Russian Federation
Russian Federation
N. L. Vinnitskaya
ФГУ ГНИЦПМ Росмедтехнологии, Москва
Russian Federation
Russian Federation
References
1. Второй пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии// Кардиоваскулярная терапия и профилактика, 3 (3) ч.1,2004 стр. 105-120.
2. Российские рекомендации по диагностике и лечению стабильной стенокардии// Приложение к журналу Кардиоваскулярная терапия и профилактика 2004.
3. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр)// Сердечная недостаточность 2006, 8,№2. стр 1-35
4. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context//Lancet 1990, 335; 827-838.
5. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study// Hypertension 1991; 17: 570-88.
6. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice// JACC 1995; 25: 1327-32.
7. Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors// Diabetes Care 1991, 14 (suppl 4):39-47.
8. Lithell H: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism// Diabetes Care 1991, 14:203-209.
9. Reneland R, Alvares E, Andersson PL, et al. Induction of insulin resistance by beta-blockade but not by ACE-inhibition: long-term treatment with atenolol or trandolapri//J.Hum. Hypertens 2000;14; 175-180.
10. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol or HCTZ alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance// Hypertension 1985,7:1008-1016.
11. The Working Group on Hypertension in diabetes: Statement on hypertension in diabetes mellitus. Final report.//Arch Int. Med 1987,147:830-842.
12. Pool PE, Seagren SC, Salel AF: Metabolic consequences of treating hypertension// Am J Hypertens 1991,4:494-502
13. Weidmann P, Feffier C, Saxenhofer H, et al: Serum lipoproteins during treatment with antihypertensive drugs// Drugs 1988, 35 (suppl 6):118-134.
14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, at al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial// JAMA December 3, 2003; №21 (Vol 290):2805- 16.
15. The ALLHAT Officers and Coordinators Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic// JAMA 2002;288:2981-97.
16. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol// Lancet 2002,359:995-1003.
17. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis// Lancet 2007; 369: 210-207.
18. Beevers D.G. The end of beta-bockers for uncomplicated hypertension? //Lancet.- 2005, 366; 1510-1512.
19. Hepertension: management of hypertension in adults in primary care. NICE. /BHS.June 2006.www.nice.org.uk/CGO34.GL
20. Рекомендации по диагностике и лечению артериальной гипертонии (третий пересмотр)// Кардиоваскулярная терапия и профилактика. 2008, №6. Приложение.
21. von Arnim T, TIBBS Investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a mutticenter trial comparing bisoprolol and nifedipine// JACC1995; 25: 231-8.
22. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial// Lancet 1999; 353: 9-13.
23. Fritps G. And Weiner L. Effects of bisoprolol, dosed once daily, on blood pressure, serum lipids and HDL-cholesterol in patients with essential hypertension// J.Cardiovasc.Pharmacol., 1987, 32;77
24. Janka H.U. et al. Influence of bisoprolol on blood glucose, glucosuria and hemoglobin A in non-insulin – dependent diabetics // Cardiovasc.Pharmacol., 1986. 8 (Suppl.11); 110.
25. Wang B, Song WH, Liu GZ; Multi-center Cooperation Group of Bisoprolol. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus// Zhonghua Nei Ke Za Zhi. 2005 Jul;44(7):503-5. Chinese.
26. Лазерная допплеровская флоуметрия микроциркуляции крови/ Под редакцией А.И. Крупаткина, В.В. Сидорова. Руководство для врачей. Медицина. 2005.
Review
For citations:
Nebieridze D.V., Kulieva R.G., Sargsyan V.D., Vinnitskaya N.L. BETA-ADRENOBLOCKER THERAPY IN ARTERIAL HYPERTENSION, METABOLIC DISTURBANCES, AND TYPE 2 DIABETES MELLITUS. Russian Journal of Cardiology. 2009;(4):64-67. (In Russ.)
Views:
642
Email this article 